Hereditary hemochromatosis

Gene discovery and its implications for population-based screening

Wylie Burke, Elizabeth Thomson, Muin J. Khoury, Sharon M. McDonnell, Nancy Press, Paul C. Adams, James C. Barton, Ernest Beutler, Gary Brittenham, Allen Buchanan, Ellen Wright Clayton, Mary E. Cogswell, Eric M. Meslin, Arno G. Motulsky, Lawrie W. Powell, Elliott Sigal, Benjamin S. Wilfond, Francis S. Collins

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

Objective. - To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers. Participants. - An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information. Evidence. - The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder. Consensus Process. - Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period. Conclusions. - Genetic testing is not recommended at this time in population- based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype- phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.

Original languageEnglish (US)
Pages (from-to)172-178
Number of pages7
JournalJournal of the American Medical Association
Volume280
Issue number2
DOIs
StatePublished - Jul 8 1998
Externally publishedYes

Fingerprint

Hemochromatosis
Genetic Association Studies
Genetic Testing
Population
Consensus
Mutation
Penetrance
Uncertainty
National Human Genome Research Institute (U.S.)
Genotype
Stereotyping
Inborn Genetic Diseases
Iron Overload
Molecular Epidemiology
Gastroenterology
Centers for Disease Control and Prevention (U.S.)
Health Policy
Natural History
Molecular Biology
Iron

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Burke, W., Thomson, E., Khoury, M. J., McDonnell, S. M., Press, N., Adams, P. C., ... Collins, F. S. (1998). Hereditary hemochromatosis: Gene discovery and its implications for population-based screening. Journal of the American Medical Association, 280(2), 172-178. https://doi.org/10.1001/jama.280.2.172

Hereditary hemochromatosis : Gene discovery and its implications for population-based screening. / Burke, Wylie; Thomson, Elizabeth; Khoury, Muin J.; McDonnell, Sharon M.; Press, Nancy; Adams, Paul C.; Barton, James C.; Beutler, Ernest; Brittenham, Gary; Buchanan, Allen; Clayton, Ellen Wright; Cogswell, Mary E.; Meslin, Eric M.; Motulsky, Arno G.; Powell, Lawrie W.; Sigal, Elliott; Wilfond, Benjamin S.; Collins, Francis S.

In: Journal of the American Medical Association, Vol. 280, No. 2, 08.07.1998, p. 172-178.

Research output: Contribution to journalArticle

Burke, W, Thomson, E, Khoury, MJ, McDonnell, SM, Press, N, Adams, PC, Barton, JC, Beutler, E, Brittenham, G, Buchanan, A, Clayton, EW, Cogswell, ME, Meslin, EM, Motulsky, AG, Powell, LW, Sigal, E, Wilfond, BS & Collins, FS 1998, 'Hereditary hemochromatosis: Gene discovery and its implications for population-based screening', Journal of the American Medical Association, vol. 280, no. 2, pp. 172-178. https://doi.org/10.1001/jama.280.2.172
Burke, Wylie ; Thomson, Elizabeth ; Khoury, Muin J. ; McDonnell, Sharon M. ; Press, Nancy ; Adams, Paul C. ; Barton, James C. ; Beutler, Ernest ; Brittenham, Gary ; Buchanan, Allen ; Clayton, Ellen Wright ; Cogswell, Mary E. ; Meslin, Eric M. ; Motulsky, Arno G. ; Powell, Lawrie W. ; Sigal, Elliott ; Wilfond, Benjamin S. ; Collins, Francis S. / Hereditary hemochromatosis : Gene discovery and its implications for population-based screening. In: Journal of the American Medical Association. 1998 ; Vol. 280, No. 2. pp. 172-178.
@article{bd822a3fd5b540f9a3ceb5f5fbc0aa99,
title = "Hereditary hemochromatosis: Gene discovery and its implications for population-based screening",
abstract = "Objective. - To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers. Participants. - An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information. Evidence. - The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder. Consensus Process. - Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period. Conclusions. - Genetic testing is not recommended at this time in population- based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype- phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.",
author = "Wylie Burke and Elizabeth Thomson and Khoury, {Muin J.} and McDonnell, {Sharon M.} and Nancy Press and Adams, {Paul C.} and Barton, {James C.} and Ernest Beutler and Gary Brittenham and Allen Buchanan and Clayton, {Ellen Wright} and Cogswell, {Mary E.} and Meslin, {Eric M.} and Motulsky, {Arno G.} and Powell, {Lawrie W.} and Elliott Sigal and Wilfond, {Benjamin S.} and Collins, {Francis S.}",
year = "1998",
month = "7",
day = "8",
doi = "10.1001/jama.280.2.172",
language = "English (US)",
volume = "280",
pages = "172--178",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Hereditary hemochromatosis

T2 - Gene discovery and its implications for population-based screening

AU - Burke, Wylie

AU - Thomson, Elizabeth

AU - Khoury, Muin J.

AU - McDonnell, Sharon M.

AU - Press, Nancy

AU - Adams, Paul C.

AU - Barton, James C.

AU - Beutler, Ernest

AU - Brittenham, Gary

AU - Buchanan, Allen

AU - Clayton, Ellen Wright

AU - Cogswell, Mary E.

AU - Meslin, Eric M.

AU - Motulsky, Arno G.

AU - Powell, Lawrie W.

AU - Sigal, Elliott

AU - Wilfond, Benjamin S.

AU - Collins, Francis S.

PY - 1998/7/8

Y1 - 1998/7/8

N2 - Objective. - To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers. Participants. - An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information. Evidence. - The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder. Consensus Process. - Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period. Conclusions. - Genetic testing is not recommended at this time in population- based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype- phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.

AB - Objective. - To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers. Participants. - An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information. Evidence. - The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder. Consensus Process. - Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period. Conclusions. - Genetic testing is not recommended at this time in population- based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype- phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.

UR - http://www.scopus.com/inward/record.url?scp=0032496881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032496881&partnerID=8YFLogxK

U2 - 10.1001/jama.280.2.172

DO - 10.1001/jama.280.2.172

M3 - Article

VL - 280

SP - 172

EP - 178

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 2

ER -